NOVARTIS PHARMACEUTICALS UK LIMITED

Information

Name

Type

Company

Roles

Supplier

Company Size

Large

Company Number

Incorporation Date

Website

http://www.novartis.co.uk

Address

2nd Floor, The Westworks Building White City Place, 195 Wood Lane, London, United Kingdom, W12 7FQ

Suppliers

Unlock the full supplier list, free!

Sign up to unlock the full list of suppliers associated with NOVARTIS PHARMACEUTICALS UK LIMITED
Sign up free

Contracts awarded to NOVARTIS PHARMACEUTICALS UK LIMITED

The contracts that NOVARTIS PHARMACEUTICALS UK LIMITED have been awarded to supply. Click on the contract to view more detailed information and view the full details about the contract won.

Award

Published 4 weeks ago

NOVARTIS PHARMACEUTICALS UK LTD (WT) - WT2024-11, WT2024-12, WT2024-13 - RIBOCICLIB [KISQALI] (AS SUCCINATE) 200 mg Tablets, SECUKINUMAB (COSENTYX) 150 mg in 1mL & 300 mg in 2mLInjections

Supply of RIBOCICLIB [KISQALI] (AS SUCCINATE) 200 mg Tablets to meet clinical need in the Western Trust until 15/08/2027. Supply of SECUKINUMAB (COSENTYX) 150 mg in 1mL & 300mg in 2mL Injections to meet clinical need in the Western Trust until 03/08/2025.

£1,532,304
Award

Published 4 weeks ago

NHS National Framework for Medical Retinal Vascular Treatments 1 August 2024

Project title: NHS National Framework for Medical Retinal Vascular Treatments 1 August 2024 Offer reference number CM/PHS/24/5707 Period of framework: 1 August 2024 to 31 July 2025. with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months Published By: Medicines Procurement and Supply Chain – NHS Medicines Value & Access, NHS England The Procurement relates to the supply of medical retinal vascular Anti Veg-F and Intravitreal Corticosteroid medicines used in medical retinal vascular services for the NHS in England.

£9
Award

Published 1 month ago

NHS Branded Medicines Tranche Framework for London and South of England

NHS Branded Medicines Tranche Framework for London and South of England - 1 September 2024 Offer reference number: CM/PHR/22/5689 CM/PHR/22/5689/01 - NHS Framework for Branded Medicines - London & South of England Tranche A. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. CM/PHR/22/5689/02 - NHS Framework for Branded Medicines - London & South of England Tranche B. Period of framework: 1 September 2024 to 31 August 2026 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. CM/PHR/22/5689/03 - NHS Framework for the supply of Omalizumab and Diroximel Fumarate for the Midlands & East and North of England. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.

£39
Award

Published 6 months ago

Generic Drugs - Tablets and Capsules

Generic Drugs - Tablets & Capsules

£20,450,823

NOVARTIS PHARMACEUTICALS UK LIMITED

Information

Name

Type

Roles

Company Size

Company Number

Incorporation Date

Website

Address

Suppliers

Contracts awarded to NOVARTIS PHARMACEUTICALS UK LIMITED

NOVARTIS PHARMACEUTICALS UK LTD (WT) - WT2024-11, WT2024-12, WT2024-13 - RIBOCICLIB [KISQALI] (AS SUCCINATE) 200 mg Tablets, SECUKINUMAB (COSENTYX) 150 mg in 1mL & 300 mg in 2mLInjections

NHS National Framework for Medical Retinal Vascular Treatments 1 August 2024

NHS Branded Medicines Tranche Framework for London and South of England

Generic Drugs - Tablets and Capsules

Contacts

Statistics (1 Year)

Contracts Won

Total Won

Average Win